MUC1 and pancreatic neoplasm: Recent studies in pancreatic cancer treatment demonstrate that targeting tumor-associated MUC1 (tMUC1) with the monoclonal antibody TAB004 overcomes anoikis resistance by specifically binding to tMUC1, reducing cancer cell viability and promoting its degradation (17).